Related Experiment Video
Updated: Mar 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
Teruhide Yamaguchi1, Eriko Uchida1,2
1Department of Pharmaceutical Sciences, Nihon Pharmaceutical University, Saitama, Japan.
Abstract:
Oncolytic viruses, which include both naturally occurring wild-type viruses/attenuated viruses and genetically modified viruses, have recently been developed for use in innovative cancer therapies. Genetically modified oncolytic viruses possess the unique ability to replicate conditionally as a unique gene therapy product. Since oncolytic viruses exhibit prolonged persistence in patients, viral shedding and transmission to third parties should be major concerns for clinical trials along with the clinical safety and efficacy. Accordingly, studies are now underway to establish the safety and efficacy of oncolytic viruses.
Related Concept Videos
Preclinical Development: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation

